Bharat Biotech's indigenous COVID-19 vaccine 'COVAXIN' gets approval for phase I & II human clinical trials
Tuesday, 30 June 2020 ()
The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous inactivated vaccine was developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad. |
|
|||